Skip to main content
. 2017 Feb 27;22(3):304–310. doi: 10.1634/theoncologist.2016-0253

Figure 2.

image

Metastatic non‐small cell lung cancer estimated overall survival by year of diagnosis, 2015 versus 1990. When the proportion of patients receiving systemic therapy in 2015 was increased by 10% (Scenario 1) or 30% (Scenario 2), the improvement in survival relative to 1990 increased by 5.1 months (39,700 population life years) and 6.9 months (53,800 population life years), respectively.

Abbreviations: NSCLC, non‐small cell lung cancer.